OmniAb Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

OmniAb şirketinin toplam hissedar öz sermayesi $291.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $331.6M ve $39.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$59.38m
Eşitlik	US$291.73m
Toplam yükümlülükler	US$39.83m
Toplam varlıklar	US$331.55m

Son finansal sağlık güncellemeleri

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Sep 14

Recent updates

OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 15

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Sep 14

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

Jul 15

The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Mar 26

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

Feb 28

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Jan 15

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Nov 11

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Aug 13

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

May 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OABI 'nin kısa vadeli varlıkları ( $66.6M ) kısa vadeli yükümlülüklerini ( $14.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: OABI şirketinin kısa vadeli varlıkları ( $66.6M ) uzun vadeli yükümlülüklerini ( $25.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OABI borçsuzdur.

Borcun Azaltılması: OABI un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OABI şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: OABI tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

OmniAb Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Recent updates

OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates

OmniAb, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

OmniAb, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

OmniAb, Inc., Annual General Meeting, Jun 18, 2024

OmniAb, Inc. to Report Q1, 2024 Results on May 09, 2024

Now 21% undervalued after recent price drop

President exercised options and sold US$98k worth of stock

President exercised options to buy US$1.3m worth of stock.

President recently bought US$1.2m worth of stock

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

OmniAb, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President exercised options and sold US$105k worth of stock

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Forecast to breakeven in 2026

OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference

President recently bought US$1.0m worth of stock

Executive VP of Finance & CFO exercised options and sold US$78k worth of stock

Consensus revenue estimates fall by 22%

President recently bought US$406k worth of stock

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee

OmniAb, Inc. Appoints Steve Love to its Board of Directors and as Audit Committee Chair

OmniAb, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Now 20% undervalued

President recently bought US$247k worth of stock

Consensus revenue estimates fall by 14%

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Now 22% undervalued

Omniab Announces the Passing of Director Sunil Patel

OmniAb, Inc. to Report Q2, 2023 Results on Aug 10, 2023

President recently bought US$520k worth of stock

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 10%

President recently bought US$1.5m worth of stock

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President recently bought US$565k worth of stock

Independent Director recently bought US$84k worth of stock

President recently bought US$1.0m worth of stock

No independent directors

President recently bought US$276k worth of stock

Chairman exercised options to buy US$533k worth of stock.

OmniAb, Inc. completed the acquisition of Avista Public Acquisition Corp. II (NasdaqCM:AHPA) (APAC) from Avista Capital Holdings, L.P., Polar Asset Management Partners Inc., Citadel Advisors LLC, HGC Investment Management Inc., Beryl Capital Management LLC and others.

OmniAb, Inc. Appoint Board of Directors

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin